Eli Lilly and Co. received a warning letter from the FDA citing its lack of "sufficient corrective actions" on manufacturing violations at a Puerto Rican plant that produces the active ingredient in diabetes drug Humalog. A Lilly spokesman said the drugmaker is working to address the concern and that the matter has "no safety and efficacy implications for patients."

Related Summaries